BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 36707090)

  • 1. SARS-CoV-2 infections in pediatric and young adult recipients of chimeric antigen receptor T-cell therapy: an international registry report.
    McNerney KO; Richards RM; Aguayo-Hiraldo P; Calkoen FG; Talano JA; Moskop A; Balduzzi A; Krajewski J; Dave H; Vatsayan A; Callahan C; Liu H; Li Y; Davis KL; Maude SL
    J Immunother Cancer; 2023 Jan; 11(1):. PubMed ID: 36707090
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of SARS-CoV-2 in Hematopoietic Stem Cell Transplantation and Chimeric Antigen Receptor T Cell Therapy Recipients.
    Mushtaq MU; Shahzad M; Chaudhary SG; Luder M; Ahmed N; Abdelhakim H; Bansal R; Balusu R; DeJarnette S; Divine C; Kribs R; Shune L; Singh AK; Ganguly S; Abhyankar SH; McGuirk JP
    Transplant Cell Ther; 2021 Sep; 27(9):796.e1-796.e7. PubMed ID: 34256172
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcomes and Management of the SARS-CoV2 Omicron Variant in Recipients of Hematopoietic Cell Transplantation and Chimeric Antigen Receptor T Cell Therapy.
    Infante MS; Nemirovsky D; Devlin S; DeWolf S; Tamari R; Dahi PB; Lee YJ; Chung DJ; Politikos I; Barker J; Giralt SA; Babady NE; Ramanathan L; Papanicolaou GA; Seo S; Kamboj M; Perales MA; Shah GL
    Transplant Cell Ther; 2024 Jan; 30(1):116.e1-116.e12. PubMed ID: 37806446
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune Responses to SARS-CoV-2 Vaccination in Young Patients with Anti-CD19 Chimeric Antigen Receptor T Cell-Induced B Cell Aplasia.
    Jarisch A; Wiercinska E; Huenecke S; Bremm M; Cappel C; Hauler J; Rettinger E; Soerensen J; Hellstern H; Klusmann JH; Ciesek S; Bonig H; Bader P
    Transplant Cell Ther; 2022 Jul; 28(7):366.e1-366.e7. PubMed ID: 35472554
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outcomes and risk factors of SARS-CoV-2 omicron variant in B-cell lymphoma patients following CD19 targeted CAR-T therapy.
    Xiao X; Chen P; Zhong Y; Luo X; Liu Y; Lu Y; Jin X; Qian W; Han W; Liang A; Liu H
    Cancer Med; 2023 Nov; 12(22):20838-20846. PubMed ID: 37962082
    [TBL] [Abstract][Full Text] [Related]  

  • 6. State of the CAR-T: Risk of Infections with Chimeric Antigen Receptor T-Cell Therapy and Determinants of SARS-CoV-2 Vaccine Responses.
    Meir J; Abid MA; Abid MB
    Transplant Cell Ther; 2021 Dec; 27(12):973-987. PubMed ID: 34587552
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SARS-CoV-2 infection in immunocompromised patients: humoral versus cell-mediated immunity.
    Wei J; Zhao J; Han M; Meng F; Zhou J
    J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32727811
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Characteristics and impact factors of SARS-CoV-2 infection in adult patients with relapsed/refractory B-cell non-Hodgkin lymphoma receiving chimeric antigen receptor T-cell therapy].
    Ge T; Liu H; Wang ZH; Cao Y; Zhang YC; Huang L; Qian WB; Zhou XX
    Zhonghua Xue Ye Xue Za Zhi; 2023 Oct; 44(10):825-831. PubMed ID: 38049334
    [No Abstract]   [Full Text] [Related]  

  • 9. Infectious complications following CAR-t cell therapy for B cell non-Hodgkin lymphoma: a single-center experience and review of the literature.
    Mercadal S; Gomez CA; Lee CJ; Couriel DR
    Ann Hematol; 2023 Jul; 102(7):1837-1843. PubMed ID: 37246975
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-BCMA CAR T administration in a relapsed and refractory multiple myeloma patient after COVID-19 infection: a case report.
    Madduri D; Parekh S; Campbell TB; Neumann F; Petrocca F; Jagannath S
    J Med Case Rep; 2021 Feb; 15(1):90. PubMed ID: 33608053
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcomes in Hematopoietic Cell Transplant and Chimeric Antigen Receptor T Cell Therapy Recipients with Pre-Cellular Therapy SARS-CoV-2 Infection.
    Nimgaonkar I; Yoke LH; Roychoudhury P; Flaherty PW; Oshima MU; Weixler A; Gauthier J; Greninger AL; Mielcarek M; Boeckh M; Liu C; Hill JA
    Clin Infect Dis; 2024 Mar; ():. PubMed ID: 38427848
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SARS-CoV-2-reactive antibody waning, booster effect and breakthrough SARS-CoV-2 infection in hematopoietic stem cell transplant and cell therapy recipients at one year after vaccination.
    Piñana JL; Martino R; Vazquez L; López-Corral L; Pérez A; Chorão P; Avendaño-Pita A; Pascual MJ; Sánchez-Salinas A; Sanz-Linares G; Olave MT; Arroyo I; Tormo M; Villalon L; Conesa-Garcia V; Gago B; Terol MJ; Villalba M; Garcia-Gutierrez V; Cabero A; Hernández-Rivas JÁ; Ferrer E; García-Cadenas I; Teruel A; Navarro D; Cedillo Á; Sureda A; Solano C;
    Bone Marrow Transplant; 2023 May; 58(5):567-580. PubMed ID: 36854892
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

  • 14. COVID-19 in New South Wales children during 2021: severity and clinical spectrum.
    Williams P; Koirala A; Saravanos GL; Lopez LK; Glover C; Sharma K; Williams T; Carey E; Shaw N; Dickens E; Sitaram N; Ging J; Bray P; Crawford NW; McMullan B; Macartney K; Wood N; Fulton EL; Lau C; Britton PN
    Med J Aust; 2022 Sep; 217(6):303-310. PubMed ID: 35851698
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The burden of SARS-CoV-2 in patients receiving chimeric antigen receptor T cell immunotherapy: everything to lose.
    Luque-Paz D; Sesques P; Wallet F; Bachy E; Ader F
    Expert Rev Anti Infect Ther; 2022 Sep; 20(9):1155-1162. PubMed ID: 35838042
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcomes following SARS-CoV-2 infection in liver transplant recipients: an international registry study.
    Webb GJ; Marjot T; Cook JA; Aloman C; Armstrong MJ; Brenner EJ; Catana MA; Cargill T; Dhanasekaran R; García-Juárez I; Hagström H; Kennedy JM; Marshall A; Masson S; Mercer CJ; Perumalswami PV; Ruiz I; Thaker S; Ufere NN; Barnes E; Barritt AS; Moon AM
    Lancet Gastroenterol Hepatol; 2020 Nov; 5(11):1008-1016. PubMed ID: 32866433
    [TBL] [Abstract][Full Text] [Related]  

  • 17. B-cell malignancies and COVID-19: a narrative review.
    Luque-Paz D; Sesques P; Wallet F; Bachy E; Ader F;
    Clin Microbiol Infect; 2023 Mar; 29(3):332-337. PubMed ID: 36336236
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of Multiple SARS-CoV-2 Vaccine Doses in Patients with B Cell Hematologic Malignancies Receiving Chimeric Antigen Receptor T Cell Therapy: A Contemporary Cohort Analysis.
    Abid MB; Rubin M; Szabo A; Longo W; Fenske TS; McCoy C; Lorge A; Abedin S; D'Souza A; Dhakal B; Shah NN; Hamadani M
    Transplant Cell Ther; 2024 Mar; 30(3):285-297. PubMed ID: 38142942
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk of Admission to the Pediatric Intensive Care Unit for SARS-CoV-2 Delta and Omicron Infections.
    Recher M; Leteurtre S; Javouhey E; Morin L; Baudin F; Rambaud J; Mortamet G; Hubert H; Angoulvant F; Levy M;
    J Pediatric Infect Dis Soc; 2023 Apr; 12(4):189-197. PubMed ID: 36786499
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CAR T-cell treatment during the COVID-19 pandemic: Management strategies and challenges.
    Hu Y; Tan Su Yin E; Yang Y; Wu H; Wei G; Su J; Cui Q; Jin A; Yang L; Fu S; Zhou J; Qiu L; Zhang X; Liang A; Jing H; Li Y; Blaise D; Mohty M; Nagler A; Huang H
    Curr Res Transl Med; 2020 Aug; 68(3):111-118. PubMed ID: 32620465
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.